Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The patient was treated as part of a multinational clinical trial sponsored by Immunophotonics (IP-IIO-622) that will assess the safety and efficacy of its lead asset, IP-001. The protocol has been approved by regulatory authorities in the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating.  Patients in this trial are being enrolled for treatment of colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma.  Read more: (Official Press Release)